The future of drug safety: Promoting and protecting the health of the public

The Future of Drug Safety: Promoting and Protecting the Health of the Public

Volumn , Issue , 2007, Pages 1-332

  Baciu, Alina ^a   Stratton, Kathleen ^a   Burke, Sheila P ^b  

^a Smithsonian Institution ^*

^b SMITHSONIAN INSTITUTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84988666676     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.17226/11750     Document Type: Book

References (286)

1. Consumers Union. 2005. NEWS-IOM Panel Urged to Immediately Recommend that Congress Toughen Drug Safety Laws to Save Lives: Consumers Union Testifies Today That Obvious Safety Problems Need Action Now. [Online]. Available: http://www.pharmalive. com/news/print.cfm?articleid=247043 [accessed June 9, 2005].
2. Grassley C. 2005. S.930: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. 109th Congress.
3. Harris Interactive. 2005. The Public Has Doubts About the Pharmaceutical Industry's Willingness to Publish Safety Information About Their Drugs in a Timely Manner. [Online]. Available: http://www.harrisinteractive.com/news/printerfriend/index.asp?NewsID=882 [accessed March 10, 2006].
4. NCL (National Consumers League). 2005. Comments of the National Consumers League to DKT. No. 2005N-0394 , Communication of Drug Safety Information. [Online]. Available: http://www.nclnet.org/advocacy/health/letter_drugsafety_01062006.htm [accessed September 16, 2006].
5. PricewaterhouseCoopers' Health Research Institute. 2005. Recapturing the Vision: Integrity Driven Performance in the Pharmaceutical Industry. [Online]. Available: http://www. pwc.com/extweb/pwcpublications.nsf/docid/EE74BACB6DE454768525702A00630CFF [accessed February 20, 2006].
6. US PIRG (United States Public Interest Research Group). 2006. Drug Safety. [Online]. Available: http://uspirg.org/uspirg.asp?id2=17568&id3=US& [accessed September 16, 2006].
7. Applebaum A (The Washington Post). 2005. The Drug Approval Pendulum. [Online]. Available: http://www.washingtonpost.com/wp-dyn/articles/A48135-2005Apr12.html [accessed April 21, 2005].
8. CDER (Center for Drug Evaluation and Research). 1998. Guideline for the Format and Content of the Clinical and Statistical Sections of an Application. Rockville, MD: CDER.
9. Cockburn IM. 2004. The changing structure of the pharmaceutical industry. Health Aff (Millwood) 23(1):10-22.
10. DHEW (Department of Health Review Panel on New Drug Regulation), Dorsen N, Weiner N, Astin AV, Cohen MN, Cornelius CE, Hamilton RW, Rall DP. 1977. Final Report. Washington, DC: DHEW.
11. DHHS (Department of Health and Human Services), FDA, Task Force on Risk Management. 1999. Managing the Risks from Medical Product Use: Creating a Risk Management Framework. [Online]. Available: http://www.fda.gov/oc/tfrm/riskmanagement.pdf [accessed October 10, 2005].
12. FDA (Food and Drug Administration). 2004. Innovation Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. [Online]. Available: http://www.fda. gov/oc/initiatives/criticalpath/whitepaper.html [accessed October 10, 2005].
13. FDA. 2005a. Establishment of Prescription Drug User Fee rates for fiscal year 2006. Fed Reg 70(146):44106-44109.
14. FDA. 2005b. White Paper, Prescription Drug User Fee Act (PDUFA): Adding Resources and Improving Performance in FDA Review of New Drug Applications. [Online]. Available: http://www.fda.gov/oc/pdufa/PDUFAWhitePaper.pdf [accessed December 5, 2005].
15. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. 1999. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 281(18):1728-1734.
16. Ganslaw LS. Drug safety: new legal/regulatory approaches. FDLI July/August (4):7-10.
17. Geraghty LN (The New York Times). 2006. Doctors Fear Acne Drug Rules Go Too Far. [Online]. Available: http://www.nytimes.com/2006/01/12/fashion/thursdaystyles/12skin. html [accessed January 13, 2006].
18. Gwynne P, Heebner G. 2001. Technologies in drug discovery/drug development: the next generation. Science Aug:1-17.
19. Hart C. 1999. Drug approvals: safe at any speed? Mod Drug Disc 2(5):25-26, 28.
20. Herper M. 2005. Five Ways to Fix the FDA. [Online]. Available: http://www.forbes.com/healthcare/ 2005/01/12/cx_mh_0112fdaintro.html [accessed July 1, 2005].
21. Joint Commission on Prescription Drug Use. 1980. Report of the Joint Commission on Prescription Drug Use. KF3869.R4. Rockville, MD.
22. Kaiser Family Foundation. 2005. Kaiser HealthPoll Report Views on Prescription Drugs and the Pharmaceutical Industry. [Online]. Available: http://www.kff.org/healthpollreport/ feb_2005/upload/full_report.pdf [accessed September 22, 2005].
23. Kleinke JD, Gottlieb S. 1998. Is the FDA approving drugs too fast? Probably not-but drug recalls have sparked debate. [see comment]. BMJ 317(7163):899.
24. Landow L. 1999. FDA approves drugs even when experts on its advisory panels raise safety questions. BMJ 318(7188):944.
25. Lurie P, Wolfe SM. 1998. FDA Medical Officers Report Lowers Standards Permit Dangerous Drug Approvals. [Online]. Available: http://www.citizen.org/publications/release. cfm?ID=7104 [accessed October 15, 2005].
26. Lurie P, Sasich LD. 1999. Safety of FDA-approved drugs. JAMA 282(24):2297-2298.
27. Markel H. 2005. Why America needs a strong FDA. JAMA 294(19):2489-2491.
28. Moses H, Dorsey ER, Matheson DHM, Their SO. 2005. Financial anatomy of biomedical research. JAMA 294(11):1333-1342.
29. PricewaterhouseCoopers' Health Research Institute. 2005. Recapturing the Vision:Integrity Driven Performance in the Pharmaceutical Industry. [Online]. Available: http://www. pwc.com/extweb/pwcpublications.nsf/docid/EE74BACB6DE454768525702A00630CFF [accessed March 10, 2006].
30. Stergachis A, Hazlet T. 2002. Pharmacoepidemiology. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. New York: McGraw-Hill Medical. Pp. 91-97.
31. Swann JP. 1998. History of the FDA. [Online]. Available: http://www.fda.gov/oc/history/ historyoffda/fulltext.html [accessed January 14, 2006].
32. Tatsioni A, Gerasi E, Charitidou E, Simou N, Mavreas V, Ioannidis JP. 2003. Important drug safety information on the internet: assessing its accuracy and reliability. Drug Saf 26(7):519-527.
33. Tauzin B. 2002. Reauthorization of the Prescription Drug User Fee Act. Statement at the March 6, 2002 Hearing of the Committee on Energy and Commerce. [Online]. Available: http:// energycommerce.house.gov/107/action/107-93.pdf [accessed September 14, 2006].
34. Tone B. 1999. Rushing Through? Questioning the Safety of Drug Approvals. [Online]. Available: http://www.nurseweek.com/features/99-11/fda.html [accessed July 1, 2005].
35. US House of Representatives Committee on Government Reform Minority Staff. 2006. Prescription for Harm: The Decline in FDA Enforcement Activity. [Online]. Available: http://www.democrats.reform.house.gov/Documents/20060627101434-98349.pdf [accessed August 26, 2006].
36. Wall Street Journal, Harris Interactive. 2005. The Public Has Doubts About the Pharmaceutical Industry's Willingness to Publish Safety Information About Their Drugs in a Timely Manner. [Online]. Available: http://www.harrisinteractive.com/news/printerfriend/index. asp?NewsID=882 [accessed March 10, 2006].
37. Wood AJ, Stein CM, Woosley R. 1998. Making medicines safer-the need for an independent drug safety board. N Engl J Med 339(25):1851-1854.
38. Zelenay JL. 2005. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration? Food and Drug Law J 60(2):261-338.
39. Ackermann Shiff S, Mundkur C, Shamp J. 2006. iPLEDGE: Isotretinoin Pregnancy Risk Management Program. Presented to DSaRM. [Online]. Available: http://www.fda.gov/ohrms/ dockets/ac/06/slides/2006-4202S2_05-Sponsor.ppt# [accessed February 10, 2006].
40. Adams CP, Brantner VV. 2006. Estimating the cost of new drug development: is it really $802 million? Health Aff 25(2):420-428.
41. Agres T. 2006. Drug Safety Reshaping FDA Monolith. [Online]. Available: http://www.dddmag. com/ShowPR.aspx?PUBCODE=016&ACCT=1600000100&ISSUE=0504&RELTY PE=PR&ORIGRELTYPE=PNP&PRODCODE=00000000&PRODLETT=AF [accessed September 15, 2006].
42. Ahmad SR, Goetsch RA, Marks NS. 2005. Chapter 9: spontaneous reporting in the United States. In: Strom BS, Ed. Pharmacoepidemiology. Fourth ed. West Sussex, England: John Wiley & Sons. Pp. 135-159.
43. Appel JL. 2002. The verdict from ALLHAT-thiazide diuretics are the preferred initial therapy for hypertension. JAMA 288(23):3030-3042.
44. Beck JM, Azari ED. 1998. FDA, off-label use, and informed consent: debunking myths and misconceptions. Food Drug Law J 53(1):71-104.
45. Bilstad J (HHS, FDA, CDER, Office of Drug Evaluation II). 1997. Letter to Knoll Pharmaceutical Company. Rockville, MD.
46. Boodman SG. 2006. Many Drug Uses Don't Rest on Strong Science. [Online]. Available: http:// www.washingtonpost.com/wp-dyn/content/article/2006/05/22/AR2006052201428.html? referrer=emailarticle [accessed July 3, 2006].
47. Brownfield ED, Bernhardt JM, Phan JL, Williams MV, Parker RM. 2004. Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement. J Health Commun 9(6):561-562.
48. CDC (Centers for Disease Control and Prevention). 1999. Ten great public health achievements- United States 1900-1999. MMWR 48(12):241-243.
49. CDER (Center for Drug Evaluation and Research). 2004. Clinical Review Template, MAPP 6010.3. [Online]. Available: http://www.fda.gov/cder/mapp/6010.3.pdf [accessed May 19, 2006].
50. CDER. 2005a. Drug Safety and Risk Management Advisory Committee (DSaRM). [Online]. Available: http://www.fda.gov/OHRMS/DOCKETS/AC/05/agenda/2005-4143A1_Final. htm [accessed May 19, 2005].
51. CDER. 2005b. Review Management: Risk Management Plan Activities in OND and ODS, MAPP 67 00.1. [Online]. Available: http://www.fda.gov/cder/mapp/6700.1.pdf [accessed November 14, 2005].
52. CDER. 2005c. Drug Safety Oversight Board (DSB), MAPP 4151 -3. [Online]. Available: http:// www.fda.gov/cder/mapp/4151-3.pdf [accessed June 20, 2005].
53. CDER. 2006. Medication Guides. [Online]. Available: www.fda.gov/cder/offices/ods/medication_ guides.htm [accessed July 6, 2006].
54. CDER, FDA, DHHS. 1998. The CDER Handbook. [Online]. Available: http://www.fda.gov/ cder/handbook/handbook.pdf [accessed November 14, 2005].
55. CDER, FDA, DHHS. 2005. Reviewer Guidance: Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review. [Online]. Available: http://www.fda.gov/cder/guidance/3580fnl.pdf [accessed December 30, 2005].
56. Crawford LM, Acting Commissioner of the FDA. 2005. Speech Before FDA All-Hands Briefing with New HHS Secretary Mike Leavitt. [Online]. Available: http://www.fda.gov/oc/ speeches/2005/safedrugs0215.html [accessed February 23, 2005].
57. Curran J. 2005. Merck Fought Vioxx Warning. [Online]. Available: http://www.philly.com/ mld/philly/business/12707648.htm [accessed October 10, 2005].
58. DHHS (Department of Health and Human Services). 2002. Securing the Benefits of Medical Innovation for Seniors: The Role of Prescription Drugs and Drug Coverage. [Online]. Available: http://aspe.hhs.gov/health/reports/medicalinnovation/innovation.pdf [accessed October 10, 2005].
59. DHHS, FDA (Food and Drug Administration). 2006. Critical Path Opportunities Report. [Online]. Available: http://www.fda.gov/oc/initiatives/criticalpath/reports/opp_report.pdf [accessed June 2, 2006].
60. DHHS, FDA, CDER, CBER (Center for Biologics Research). 2005. Development and Use of Risk Minimization Action Plans. [Online]. Available: http://www.fda.gov/cder/guidance/ 6358fnl.htm [accessed April 14, 2006].
61. DHHS, OIG (Office of Inspector General). 2003. FDA's Review Process for New Drug Applications: A Management Review. OEI-01-01-0059 0. Washington, DC: OIG.
62. DiMasi JA, Hansen RW, Grabowski HG. 2003. The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151-185.
63. Epstein RA. 2004. Issue Brief: Does America Have a Prescription Drug Problem?. The Perils of Ignoring the Economics of Pharmaceuticals. [Online]. Available: http://www.ipi.org/ipi/IPIPublications.nsf/PublicationLookupFullTextPDF/ E6214F2C0ADBC86C86256F260069D1E2/File/EpsteinDrugProblem.pdf [accessed July 27, 2006].
64. FDA (Food and Drug Administration). 1994. Clinical Therapeutics and the Recognition of Drug-Induced Disease. [Online]. Available: http://www.fda.gov/medwaTCH/articles/dig/ recognit.htm [accessed July 12, 2006].
65. FDA. 2002. Enclosure: PDUFA Reauthorization Performance Goals and Procedures. [Online]. Available: http://www.fda.gov/oc/pdufaIIIGoals.html [accessed June 21, 2006].
66. FDA. 2003. MedWatch Reporting by Consumers. [Online]. Available: http://www.fda.gov/ medwatch/report/consumer/consumer.htm [accessed May 24, 2005].
67. FDA. 2004a. Innovation Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. [Online]. Available: http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.pdf [accessed October 10, 2005].
68. FDA. 2004b. FDA Statement on Vioxx and Recent Allegations and the Agency's Continued Commitment to Sound Science and Peer Review. [Online]. Available: http://www.fda. gov/bbs/topics/news/2004/NEW01136.html [accessed May 12, 2005].
69. FDA. 2004c. Adverse Event Reporting System (AERS). [Online]. Available: http://www.fda. gov/cder/aers/default.htm [accessed May 24, 2005].
70. FDA. 2005a. Chapter 53 -Postmarketing Surveillance and Epidemiology: Human Drugs. [Online]. Available: http://www.fda.gov/cder/aers/chapter53.htm [accessed July 12, 2006].
71. FDA. 2005b. Guidance for Industry: Development and Use of Risk Minimization Action Plans. March 2005. Rockville, MD: FDA.
72. FDA. 2005c. Questions and Answers (Qs & As) Proposed Drug Watch Program. [Online]. Available: http://www.fda.gov/cder/guidance/6657qs&asext5-2.pdf [accessed May 6, 2005].
73. FDA. 2005d. White Paper, Prescription Drug User Fee Act (PDUFA): Adding Resources and Improving Performance in FDA Review of New Drug Applications. [Online]. Available: http://www.fda.gov/oc/pdufa/PDUFAWhitePaper.pdf [accessed December 5, 2005].
74. FDA. 2005e. FDA Fact Sheet: FDA Improvement in Drug Safety Monitoring. [Online]. Available: http://www.fda.gov/oc/factsheets/drugsafety.html [accessed February 23, 2005].
75. FDA. 2005f. Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products. April 2005. Rockville, MD: FDA.
76. FDA. 2005g. Enclosure: PDUFA Reauthorization Performance Goals and Procedures. [Online]. Available: http://www.fda.gov/cder/news/pdufagoals.htm [accessed July 3, 2006].
77. FDA. 2006a. FDA Advisory Committees. [Online]. Available: http://www.fda.gov/oc/advisory/ default.htm [accessed July 3, 2006].
78. FDA. 2006b. From Test Tube to Patient: Advisory Committees: Critical to the FDA's Product Review Process, 4th Edition. [Online]. Available: http://www.fda.gov/fdac/special/ testtubetopatient/advisory.html [accessed June 29, 2006].
79. FDA. 2006c. From Test Tube to Patient: The FDA's Drug Review Process: Ensuring Drugs Are Safe and Effective, 4th Edition. [Online]. Available: http://www.fda.gov/fdac/special/testtubetopatient/ drugreview.html [accessed June 29, 2006].
80. FDA. 2006d. Report on the performance of drug and biologics firms in conducting postmarketing commitment studies. Federal Register 71(42):10978-10979.
81. FDA, CDER. 2001a. Frequently Asked Questions on Drug Development and Investigational New Drug Applications. [Online]. Available: http://www.fda.gov/cder/about/smallbiz/faq. htm#IND [accessed June 29, 2006].
82. FDA, CDER. 2001b. FDA's Drug Review and Approval Time. [Online]. Available: http://www. fda.gov/cder/reports/reviewtimes/default.htm [accessed June 16, 2006].
83. FDA, CDER. 2005. Office of Drug Safety Annual Report FY 2004. [Online]. Available: http:// www.fda.gov/cder/offices/ods/annrep2004/ [accessed June 23, 2005].
84. FDA, CDER. 2006a. Drugs@FDA Instructions. [Online]. Available: http://www.fda.gov/cder/ drugsatfda/instructionsPrint.htm [accessed July 3, 2006].
85. FDA, CDER. 2006b. Investigational New Drug (IND) Application Process. [Online]. Available: http://www.fda.gov/cder/regulatory/applications/ind_page_1.htm#preIND [accessed June 29, 2006].
86. FDA, Office of Women's Health. 2006. Information About Pregnancy Registries. [Online]. Available: http://www.fda.gov/womens/registries/general.html [accessed July 3, 2006].
87. FDA News. 2004 (October 15). FDA Launches a Multi-Pronged Strategy to Strengthen Safeguards for Children Treated with Antidepressant Medications. [Online]. Available: http:// www.fda.gov/bbs/topics/news/2004/NEW01124.html [accessed September 15, 2006].
88. FDA News. 2006a (Janaury 18). FDA Announces New Prescription Drug Information Format to Improve Patient Safety. [Online]. Available: http://www.fda.gov/bbs/topics/news/2005/ NEW01272.html [accessed March 9, 2006].
89. FDA News. 2006b (February 9). Report Demonstrates Benefits of Earlier Meetings with FDA to Make Drug Review Process More Efficient. [Online]. Available: http://www.fda.gov/ bbs/topics/news/2006/NEW01312.html [accessed June 15, 2006].
90. FDA News. 2006c (April 18). FDA Names First Associate Center Director for Safety Policy and Communication in the Center for Drug Evaluation and Research FDA Centralizes Drug Safety Policy and Communication. [Online]. Available: http://www.fda.gov/bbs/ topics/NEWS/2006/NEW01359.html [accessed May 25, 2006].
91. Friedman MA, Woodcock J, Lumpkin MM, Shuren JE, Hass AE, Thompson LJ. 1999. The safety of newly approved medicines: do recent market removals mean there is a problem? JAMA 281(18):1728-1734.
92. Gahart MT, Duhamel LM, Dievler A, Price R. 2003. Examining the FDA's oversight of directto- consumer advertising. Health Aff (Millwood) Suppl Web Exclusives:W3-120-123.
93. GAO (Government Accountability Office). 1990. FDA Drug Review: Postapproval Risks 1976 -85 . GAO/PEMD-90-15. Washington, DC: GAO.
94. GAO. 2006. Drug Safety: Improvement Needed in FDA's Postmarket Decision-Making and Oversight Process. GAO-06-402. Washington, DC: GAO.
95. Gilber J, Henske P, Singh A. 2003. Rebuilding big pharma's business model. Bus Med Rep 21(10):1-10.
96. Gilhooley M. 2005. Heal the damage: prescription drug consumer advertisements and relative choice. J Health Law 38(1):Winter.
97. Graham DJ. 2004. Testimony of David J. Graham, M.D., M.P.H., November 18 , 2004 Before the Committee on Finance. [Online]. Available: http://www.senate.gov/~finance/hearings/ testimony/2004test/111804dgtest.pdf [accessed October 10, 2005].
98. Grassley C, Baucus M, Graham D, Singh G, Psaty B, Kweder S, Gilmartin R. 2004. FDA, Merck and Vioxx: Putting Patient Safety First? Statements at the November 18, 2004 hearing before the United States Senate Committee on Finance, United States Senate.
99. Henderson D. 2006 (February). Doc Room Stats for IOM. Personal Communication: E-mail to Stratton K (IOM Staff).
100. Hensley S, Davies P, Martinez B. 2005. Vioxx Verdict Stokes Backlash That Hit FDA, Manufacturers. [Online]. Available: http://online.wsj.com/article/0, SB112467370587619279- email,00.html [accessed October 10, 2005].
101. Huddleston, RD. 1999. FDA Clinical Investigator Site Inspections: The Sponsor's Role. [Online]. Available: http://www.findarticles.com/p/articles/mi_qa3899/is_199907/ai_ n8868995/print [accessed August 1, 2006].
102. IOM (Institute of Medince). 2007. Preventing Medication Errors. Washington, DC: The National Academies Press.
103. Kaiser Family Foundation. 2005. Prescription Drug Trends. [Online]. Available: http://www. kff.org/insurance/upload/3057-04.pdf [accessed March 10, 2006].
104. Kaitin KI. 2005. Numbers of active investigators in FDA-regulated clinical trials drop. Tufts Center for the Study of Drug Development Impact Report 7(3).
105. Kennedy DL, Uhl K, Kweder SL. 2004. Pregnancy exposure registries. Drug Saf 27(4): 215-228.
106. Lasser KE, Seger DL, Yu DT, Karson AS, Fiskio JM, Seger AC, Shah NR, Gandhi TK, Rothschild JM, Bates, DW. 2006. Adherence to black box warnings for prescription medications in outpatients. Arch Int Med Feb(166):338-344.
107. Lipsky MS, Sharp LK. 2001. From idea to market: the drug approval process. J Am Board Fam Pract 14(5):362-367.
108. Lurie P, Woodcock J, Kaitin KI. 1999. FDA drug review: the debate over safety, efficacy, and speed. Medical Crossfire 1(3):52-60.
109. Meadows M. 2002. The FDA's drug review process: ensuring drugs are safe and effective. FDA Consum 36(4):19-24.
110. Meadows M. 2003. Drug Research and Children. [Online]. Available: http://www.fda.gov/ fdac/features/2003/103_drugs.html [accessed July 12, 2006].
111. Meyer R. 2004. Letter to Amgen Inc and Danagher P, March 8, 2004. [Online]. Available: http://www.fda.gov/cder/foi/appletter/2004/21688ltr.pdf [accessed August 28, 2006].
112. Moynihan R. 2002. FDA fails to reduce accessibility of paracetamol despite 450 deaths a year. BMJ 325(7366):678.
113. NCHS (National Center for Health Statistics). 2004. Health, United States, 2004: With Chartbook on Trends in the Health of Americans with Special Feature on Drugs. Hyattsville, MD: NCHS.
114. Neergaard L. 2005. FDA Looking into Blindness-Viagra Link. [Online]. Available: http://abcnews. go.com/Health/wireStory?id=796471 [accessed May 27, 2005].
115. NHLBI (National Heart, Lung and Blood Institute). 2005. Cardiac Arrhythmia Suppression Trial (CAST). [Online]. Available: http://www.clinicaltrials.gov/ct/show/NCT00000526 [accessed July 12, 2006].
116. Okie S. 2005. Safety in numbers-monitoring risk in approved drugs. N Engl J Med 352(12): 1173-1176.
117. PhRMA (Pharmaceutical Research and Manufacturers of America). 2006. Pharmaceutical Industry Profile. Washington, DC.
118. Public Health Newswire. 2006. Drugs' Black Box Warning Violations in Outpatient Settings Putting Patients at Risk. [Online.] Available: http://www.medicalnewstoday.com/ medicalnews.php?newsid=37735 [accessed July 13, 2006].
119. Racoosin JA. 2006 (January 17). Pre-Marketing Assessment of Drug Safety. PowerPoint presentation, presented at the Institute of Medicine Workshop on Advancing the Methods and Application of Risk-Benefit Assessment of Medicines, Washington, DC. Insitute of Medicine Committee on the Assessment of the US Drug Safety System.
120. Randall, B. 2001. The US Drug Approval Process: A Primer. [Online]. Available: http://www. thememoryhole.org/crs/more-reports/RL30989.pdf [accessed June 27, 2005].
121. Ray WA, Stein CM. 2006. Reform of drug regulation-beyond an independent drug-safety board. N Engl J Med 354(2):194-201.
122. Rodriguez EM, Staffa JA, Graham DJ. 2001. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol Drug Saf 10(5):407-410.
123. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
124. Smith C, Cowan C, Sensenig A, Catlin A, the Health Accounts Team. 2005. Health spending growth slows in 2003. Health Aff 24(1):185-194.
125. Weiss Smith S. 2006. Summary of Issues: January 17 , 2006 IOM Workshop. Paper Commissioned by the IOM Committee on the Assessment of the US Drug Safety System. Washington, DC.
126. Wolfe S. 2004. Take Drugs Off the Market. [Online]. Available: http://www.usatoday.com/ news/opinion/editorials/2004-12-26-oppose_x.htm [accessed March 8, 2005].
127. Wolfe S, Public Citizen's Health Research Group. 2005. Statement by Sidney M. Wolfe, M.D., Director, Public Citizen's Health Research Group, at the Public Hearing on CDER's Current Risk Communication Strategies for Human Drugs, December 7, 2005. Washington, DC.
128. Abraham J, Davis C. 2005. A comparative analysis of drug safety withdrawals in the UK and the US (1971-1992): implications for current regulatory thinking and policy. Soc Sci Med 61(5):881-892.
129. Alonso-Zaldivar R. 2006. Without Clear Leadership, the FDA Is Falling Short. [Online]. Available: http://seattletimes.nwsource.com/html/health/2002968229_fda03.html [accessed June 5, 2006].
130. Berndt ER, Gottschalk AHB, Strobeck MW. 2005 (June). Opportunities for Improving the Drug Development Process: Results From a Survey of Industry and the FDA. National Bureau of Economic Research (NBER), Working Paper 11425.
131. BIO (Biotechnology Industry Organization). 2002 (May 21). FDA Commissioner. Letter to the Honorable George W. Bush.
132. Bridges A. 2006. Plan B Pill Snarls FDA Nominee Hearings. [Online]. Available: http://www. nexis.com [accessed August 1, 2006].
133. Carpenter D, Chernew M, Smith DG, Fendrick AM. 2003. Approval times for new drugs: does the source of funding for FDA staff matter? Health Aff (Millwood) Suppl Web Exclusives W3-618-624.
134. CDER (Center for Drug Evaluation and Research). 2004a. Clinical Review Template, MAPP 6010.3. [Online]. Available: http://www.fda.gov/cder/mapp/6010.3.pdf [accessed May 19, 2006].
135. CDER. 2004b. Documenting Differing Professional Opinions and Dispute Resolution-Pilot Program, MAPP 4151 .2. [Online]. Available: http://www.fda.gov/cder/mapp/4151.2.pdf [accessed June 20, 2005].
136. CDER. 2005. Review Management: Risk Management Plan Activities in OND and ODS, MAPP 67 00.1. [Online]. Available: http://www.fda.gov/cder/mapp/6700.1.pdf [accessed November 14, 2005].
137. CDER and FDA. 2005. Drug Safety Oversight Board Membership Center for Drug Evaluation and Research. [Online]. Available: http://www.pharmtech.com/pharmtech/article/article- Detail.jsp?id=163473 [accessed June 29, 2005].
138. CDER, FDA, DHHS. 2005. Reviewer Guidance: Conducting a Clinical Safety Review of a New Product Application and Preparing a Report on the Review. [Online]. Available: http://www.fda.gov/cder/guidance/3580fnl.pdf [accessed December 30, 2005].
139. Claver E, Llopis J, Gasco JL, Molina H, Conca FJ. 1999. Public administration: from bureaucratic culture to citizen-oriented culture. Int J Pub Sector Man 12(5):455-464.
140. Coffee JN. 1993. A Comparative Study of Organization Culture Change in Federal Agencies' Success Patterns of Long-Term Efforts. Los Angeles: University of Southern California. Cohn J. 2003. Politics, Profits & Pharma. [Online]. Available: http://www.pbs.org/wgbh/pages/ frontline/shows/prescription/politics/ [accessed September 14, 2006].
141. Cohn J. 2003. Politics, Profits & Pharma. [Online]. Available: http://www.pbs.org/wgbh/pages/ frontline/shows/prescription/politics/ [accessed September 14, 2006].
142. Consumers Union. 2005. FDA Board Told Proposed Drug Safety Reforms Are Inadequate; Major Changes Needed. [Online]. Available: http://www.consumersunion.org/pub/2005/ 04/002149print.html [accessed June 30, 2006].
143. Crawford LM. 2004. FDA Statement: FDA Acts to Strengthen the Safety Program for Marketed Drugs. [Online]. Available: http://www.fda.gov/bbs/topics/news/2004/NEW01131. html [accessed February 23, 2005].
144. Cummins SK. 2006 (February 10). New Drug Safety Initiatives & the Drug Safety Oversight Board. PowerPoint presentation to the Drug Safety and Risk Management Advisory Committee, Gaithersburg, MD: Food and Drug Administration, Center for Drug Evaluation and Research.
145. DHEW (Department of Health Review Panel on New Drug Regulation). 1977. Final Report.
146. Dorsen N, Weiner N, Astin AV, Cohen MN, Cornelius CE, Hamilton RW, Rall DP, Eds. Washington, DC.
147. DHHS (Department of Health and Human Services), FDA (Food and Drug Administration). 2005 (November 14). Prescription Drug User Fee Act (PDUFA) FDA and Stakeholders Public Meeting Transcript. Bethesda, MD.
148. DHHS, OIG (Office of Inspector General). 2003. FDA's Review Process for New Drug Applications: A Management Review. OEI-01-01-00590. Washington, DC: DHHS/OIG.
149. Dorsen N, Miller JM. 1979. The drug regulation process and the challenge of regulatory reform. Ann Intern Med 91(6):908-913.
150. Edmondson AC, Roberto MA, Bohmer RMJ, Ferlins EM, Feldman LR. 2005. The recovery window: organizational learning following ambiguous threats. In: Farjoun M, Starbuck W, Eds. Organization at the Limits: NASA and the Columbia Disaster. Blackwell. Pp. 220-245.
151. FDA (Food and Drug Administration). 1995. Appendix A: PDUFA Performance Goals, FY 1993-FY 1997. [Online]. Available: http://www.fda.gov/ope/pdufa/report95/appenda. html [accessed June 21, 2006].
152. FDA. 2002. Enclosure: PDUFA Reauthorization Performance Goals and Procedures. [Online]. Available: http://www.fda.gov/oc/pdufaIIIGoals.html [accessed June 21, 2006].
153. FDA. 2005a. Guidance for Industry: Development and Use of Risk Minimization Action Plans. March 2005. Rockville, MD: FDA.
154. FDA. 2005b. White Paper, Prescription Drug User Fee Act (PDUFA): Adding Resources and Improving Performance in FDA Review of New Drug Applications. [Online]. Available: http://www.fda.gov/oc/pdufa/PDUFAWhitePaper.pdf [accessed December 5, 2005].
155. FDA. 2005c. FDA Fact Sheet: FDA Improvement in Drug Safety Monitoring. [Online]. Available: http://www.fda.gov/oc/factsheets/drugsafety.html [accessed February 23, 2005].
156. FDA. 2005d (April). Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products. Rockville, MD: FDA.
157. FDA. 2005e. Enclosure: PDUFA Reauthorization Performance Goals and Procedures. [Online]. Available: http://www.fda.gov/cder/news/pdufagoals.htm [accessed July 3, 2006].
158. FDA. 2006a. Catalysts for Enactment of PDUFA. [Online]. Available: http://www.fda. gov/ohrms/dockets/dockets/05n0410/05n-0410-ts00010-gottleib.ppt [accessed July 11, 2006].
159. FDA. 2006b. Commissioners and Their Predecessors. [Online]. Available: http://www.fda. gov/oc/commissioners/default.htm [accessed July 12, 2006].
160. FDA NEWS. 2005 (October 19). FDA Names New Director of Drug Safety, Goals for Center for Drug Reorganization Announced. [Online]. Available: http://www.fda.gov/bbs/topics/ news/2005/new01245.html [accessed October 20, 2005].
161. Fontanarosa PB, Rennie D, DeAngelis CD. 2004. Postmarketing surveillance-lack of vigilance, lack of trust. JAMA 292(21):2647-2650.
162. GAO (Government Accountability Office). 1996. Aviation Acquisition: A Comprehensive Strategy Is Needed for Cultural Change at FAA. GAO/RCED-96-159. Washington, DC: GAO.
163. GAO. 2002. Food and Drug Administration: Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities. GAO-02-958. Washington, DC: GAO.
164. GAO. 2003. Air Traffic Control FAA's Modernization Efforts-Past, Present, and Future. Statement of Gerald L. Dillingham, Director, Physical Infrastructure Issues. GAO-04-227T. Washington, DC: GAO.
165. GAO. 2005. Decision Process to Deny Initial Application for Over-the-Counter Marketing of Emergency Contraceptive Drug Plan B Was Unusual. GAO-06-109. Washington, DC: GAO.
166. GAO. 2006. Drug Safety: Improvement Needed in FDA's Postmarket Decision-Making and Oversight Process. GAO-06-402. Washington, DC: GAO.
167. Grassley C. 2005. A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes. S.930. 109th Cong., 1st Sess. April 27, 2005.
168. Grassley C, Baucus M, Graham D, Singh G, Psaty B, Kweder S, Gilmartin R. 2004. FDA, Merck and Vioxx: Putting Patient Safety First? Statements at the November 18, 2004 hearing before the United States Senate Committee on Finance, United States Senate.
169. Harris G. 2004. At F.D.A., Strong Drug Ties and Less Monitoring. [Online]. Available: http:// www.nytimes.com/2004/12/06/health/06fda.html [accessed December 6, 2004].
170. Harris G. 2005. F.D.A. Moves Toward More Openness with the Public. [Online]. Available: http://query.nytimes.com/gst/fullpage.html?sec=health&res=9A0CEFDE1E3AF933A157 51C0A9639C8B63 [accessed July 17, 2006].
171. Harris G. 2006a. Halt Is Urged for Trials of Antibiotic in Children. [Online]. Available: http:// www.nytimes.com/2006/06/08/science/08drug.html [accessed June 8, 2006].
172. Harris G. 2006b. Approval of Antibiotic Worried Safety Officials. [Online]. Available: http:// www.nytimes.com/2006/07/19/health/19fda.html [accessed July 21, 2006].
173. Heifetz RA, Laurie DL. 1998. The work of leadership. Harvard Business Review on leadership. Harvard Business School Press. Pp. 171-199.
174. Henderson D. 2005 (December 6). Whistleblower's case casts further shadows on FDA's ties with drug makers. The Boston Globe.
175. Hendrick B. 2006 (July 21). Respiratory drugs' safety questioned. The Atlanta Journal- Constitution. p. 8A.
176. Hensley S, Davies P, Martinez B. 2005. Vioxx Verdict Stokes Backlash That Hit FDA, Manufacturers. [Online]. Available at: http://online.wsj.com/article/0, SB112467370587619279- email,00.html [accessed October 10, 2005].
177. House of Commons Health Committee. 2005a. The Influence of the Pharmaceutical Industry Fourth Report of Session 2004-05 Volume I. London: The Stationery Office Limited.
178. House of Commons Health Committee. 2005b. The Influence of the Pharmaceutical Industry Fourth Report of Session 2004-05 Volume II. London: The Stationery Office Limited.
179. IOM (Institute of Medicine). 2005 (July 20). Transcript, Meeting Two of the IOM Committee on the Assessment of the US Drug Safety System. Washington, DC: IOM.
180. Johnson L, US PIRG (United States Public Interest Research Group). 2005 (July 19). Presentation at Meeting Two of the IOM Committee on the Assessment of the US Drug Safety System. Washington, DC: Institute of Medicine.
181. Kaiser Family Foundation. 2005. Kaiser HealthPoll Report Views on Prescription Drugs and the Pharmaceutical Industry. [Online]. Available: http://www.kff.org/healthpollreport/ feb_2005/upload/full_report.pdf [accessed September 22, 2005].
182. Kaufman. 2004a (December 19). FDA's reliance on unconfirmed chiefs is faulted. Washington Post, p. A01.
183. Kaufman M. 2004b. White House Defends FDA as Drug Safety Debate Looms. [Online]. Available: http://www.washingtonpost.com/wp-dyn/articles/A11900-2004Dec19.html [accessed December 20, 2004].
184. Kets de Vries MFR, Miller D. 1986. Personality, culture, and organization. Acad Manage Rev 11(2):266-279.
185. Khademian A. 2002. Working with Culture, the Way the Job Gets Done in Public Programs. Washington, DC: CQ Press.
186. Mathews AW. 2004 (November 10). Did FDA staff minimize vioxx's red flags? Wall Street Journal.
187. Medical Officer Retention Subcommittee. 2006. Medical Officer Retention Subcommittee Recommendations and Response from S. Galson. Personal Communication: E-mail to Stratton K (Institute of Medicine Staff) from Henderson D (Food and Drug Administration Staff). June 2, 2006.
188. Miller HI. 2006. Drug Safety: Image vs. Reality. [Online]. Available: http://www.washingtontimes. com/commentary/20060321_093254_5884r_page2.htm [accessed May 25, 2006].
189. National Journal's Congress Daily. 2002. Drug group focuses on renewing user fee legislation. National Journal Group.
190. NIH (National Institutes of Health). 2006. Charter of the Advisory Committee to the Director. [Online]. Available: http://www.nih.gov/about/director/acd/acdcharter.htm [accessed September 16, 2006].
191. NRC (National Research Council). 2003. Enhancing the Vitality of the National Institutes of Health: Organizational Change to Meet New Challenges. Washington, DC: The National Academies Press.
192. O'Leary R. 2006. The Ethics of Dissent: Managing Guerrilla Government. Washington, DC: Congressional Quarterly Inc.
193. Okie S. 2005. What ails the FDA? N Engl J Med 352(11):1063-1066.
194. Olson MK. 2002. How have user fees affected the FDA? Regulation Spring:20-25.
195. Ostroff F. 2006 (May). Change in Management in Government. Harvard Business Review. PricewaterhouseCoopers' Health Research Institute. 2005. Recapturing the Vision: Integrity Driven Performance in the Pharmaceutical Industry. [Online]. Available: http://www. pwc.com/extweb/pwcpublications.nsf/docid/EE74BACB6DE454768525702A00630CFF [accessed March 10, 2006].
196. PricewaterhouseCoopers' Health Research Institute. 2005. Recapturing the Vision: Integrity Driven Performance in the Pharmaceutical Industry. [Online]. Available: http://www. pwc.com/extweb/pwcpublications.nsf/docid/EE74BACB6DE454768525702A00630CFF [accessed March 10, 2006].
197. Racoosin JA. 2006 (January 17). Pre-Marketing Assessment of Drug Safety. PowerPoint presentation, presented at the Institute of Medicine Workshop on Advancing the Methods and Application of Risk-Benefit Assessment of Medicines, Washington, DC. Institute of Medicine Committee on the Assessment of the US Drug Safety System.
198. Ray WA, Stein CM. 2006. Reform of drug regulation-beyond an independent drug-safety board. N Engl J Med 354(2):194-201.
199. Return to Flight Task Group. 2005. Final Report of the Return to Flight Task Group: Assessing the Implementation of the Columbia Accident Investigation Board Return-to-Flight Recommendations.
200. Rockoff JD. 2006. FDA Chief Took Over Plan B: In Deposition, Crawford Says He Bypassed Usual Approval Process. [Online]. Available: http://www.baltimoresun.com/news/nationworld/ bal-te.planb25may25,0,1214374.story?coll=bal-nationworld-headlines [accessed May 30, 2006].
201. Ross W. 2006. FDA at 100: alumni take its temperature: as the Food and Drug Administration prepares to celebrate its centenary. Med Mark & Media 41(5):52-56.
202. Sasich LD, Public Citizen's Health Research Group. 2006. Comments Before the Food and Drug Administration's Public Meeting on the Prescription Drug User Fee Act (PDUFA). [Online]. Available: http://www.citizen.org/publications/release.cfm?ID=6737 [accessed September 16, 2006].
203. Senate Executive Session. 2005. Nomination of Lester M. Crawford to be Commissioner of Food and Drugs, Department of Health and Human Services. S84 03.
204. Steenburg C. 2006. The Food and Drug Administration's use of postmarketing (Phase IV) study requirements: exception to the rule? Food Drug Law J 61(2):1-91.
205. Stigler G. 1971. The theory of economic regulation. Bell J Econ Manage Sci 2:2-21.
206. Thaul S. 2005. Drug Safety and Effectiveness: Issues and Action Options After FDA Approval. [Online]. Available: http://www.law.umaryland.edu/marshall/crsreports/crsdocuments/ RL3279703082005.pdf [accessed June 27, 2005].
207. Tufts Center for the Study of Drug Development. 2005. Drug safety withdrawals in the US not linked to speed of FDA approval. Tufts Center for the Study of Drug Development. Tufts CSDD Impact Report 7(5):1-4.
208. UCS (Union of Concerned Scientists). 2006a. Acting FDA Director Pledges to Address Abuse of Science. [Online]. Available: http://www.ucsusa.org/news/press_release/acting-fdadirector- pledges.html [accessed August 9, 2006].
209. UCS. 2006b. FDA Scientists Pressured to Exclude, Alter Findings; Scientists Fear Retaliation for Voicing Safety Concerns. [Online]. Available: http://www.ucsusa.org/news/press_ release/fda-scientists-pressured.html [accessed July 24, 2006].
210. Validation Times. 2002 (January 1). PhRMA opposes user fees for further FDA enforcement. Validation Times 4(1). von Eschenbach A. 2006. Nomination Hearing. Statement at the Aug. 1, 2006 Hearing of the Committee on Senate Committee on Health, Education, Labor, and Pensions.
211. von Eschenbach A. 2006. Nomination Hearing. Statement at the Aug. 1, 2006 Hearing of the Committee on Senate Committee on Health, Education, Labor, and Pensions.
212. Wall Street Journal and Harris Interactive. 2005. The Public Has Doubts About the Pharmaceutical Industry's Willingness to Publish Safety Information About Their Drugs in a Timely Manner. [Online]. Available: http://www.harrisinteractive.com/news/printerfriend/ index.asp?NewsID=882 [accessed March 10, 2006].
213. Wall Street Journal and Harris Interactive. 2006. The FDA's Reputation with the General Public Is Under Assault. [Online]. Available: http://www.harrisinteractive.com/news/ newsletters/wsjhealthnews/WSJOnline_HI_Health-CarePoll2006vol5_iss09.pdf. accessed [September 16, 2006].
214. Washington Drug Letter. 2006. Crawford Reverses Stance on Plan B Testimony. [Online]. Available: http://www.nexis.com [accessed July 26, 2006].
215. Weick KE, Sutcliffe KM. 2001. Managing the Unexpected: Assuring High Performance in and Age of Complexity. San Francisco, CA: Jossey-Bass.
216. Wolfe S. 2006. Public Citizen: The 100th Anniversary of the FDA: The Sleeping Watchdog Whose Master Is Increasingly the Regulated Industries. [Online]. Available: http://www. pharmalive.com/News/index.cfm?articleid=353196&categoryid=54 [accessed July 11, 2006].
217. Wolfe SM. 2006 (January 19). Statement before the IOM Committee on the Assessment of the US Drug Safety System. Washington, DC: Institute of Medicine.
218. Young JH. 2005 (January 25). DoD Pharmacy Programs. PowerPoint presentation at the TRICARE Conference: Fit for Life, Healthy Force, Healthy Families, Washington, DC.
219. Zelenay JL. 2005. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration? Food Drug Law J 60(2):261-338.
220. Ackermann Shiff S, Mundkur C, Shamp J. 2006. iPLEDGE: Isotretinoin Pregnancy Risk Management Program. [Online]. Available: http://www.fda.gov/ohrms/dockets/ac/06/ slides/2006-4202S2_05-Sponsor.ppt# [accessed June 22, 2006].
221. Avigan M, DalPan G. 2004. Overview of First Year Evaluation of the Isotretinoin Risk Management Program. [Online]. Available: http://www.fda.gov/ohrms/dockets/AC/04/ briefing/4017B1-06a%20FDA%20Backgrounder-ODS%20Sec%20C%20Tab%202.doc [accessed July 10, 2006].
222. Burroughs F, Walker S, Abigail Alliance for Better Access to Developmental Drugs. 2006 (January 19). PowerPoint presentation to the IOM Committee on the Assessment of the US Drug Safety System. Washington, DC: Institute of Medicine.
223. CERTS (Centers for Education & Research on Therapeutics). 2006. Ongoing Projects. [Online]. Available: http://certs.hhs.gov/projects/ongoing.html [accessed September 14, 2006].
224. Claxton K, Cohen JT, Neumann PJ. 2005a. When is evidence sufficient? Health Aff (Millwood) 24(1):93-101.
225. Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, Tappenden P, Wailoo A. 2005b. A Pilot Study of Value of Information Analysis to Support Research Recommendations for the National Institute for Clinical Excellence. [Online]. Available: http:// www.york.ac.uk/inst/che/pdf/claxtonnice.pdf [accessed June 22, 2006].
226. Clinicalstudyresults.org. 2006. Glossary. [Online]. Available: http://www.clinicalstudyresults. org/glossary/#hypothesis [accessed August 14, 2006].
227. Cohen AL, Jhung MA, Budnitz DS. 2006. Stimulant medications and attention deficithyperactivity disorder. N Engl J Med 354(21):2294-2295.
228. Davis R. 2004 (August 23). Vaccine Safety Datalink: Overview. Presentation to the Committee on Review of NIP's Research Procedures and Data Sharing Program. Washington, DC: Insitute of Medicine.
229. DHHS (Department of Health and Human Services). 2005. Request for Information on Active Surveillance Programs in the United States for the Identification of Clinically Serious Adverse Events Associated with Medical Products. RFIHHSF200601. Rockville, MD: DHHS, FBO (Federal Business Opportunities).
230. DHHS, AHRQ (Agency for Healthcare Research and Quality). 2006. Medicare Prescription Drug Data Development: Methods for Improving Patient Safety and Pharmacovigilance Using Observational Data. [Online]. Available: http://effectivehealthcare.ahrq.gov/decide/ decide.cfm?topic=12 [accessed September, 14 2006].
231. DHHS, FDA (Food and Drug Administration), CDER (Center for Drug Evaluation and Research). 2005. FDA's Communication of Drug Safety Information: Transcript, December 8, 2005. [Online]. Available: http://www.fda.gov/cder/meeting/RiskComm2005/1208fda. pdf [accessed February 13, 2006].
232. DHHS, OIG (Office of Inspector General). 2003. FDA's Review Process for New Drug Applications: A Management Review. OEI-01-01-00590. Washington, DC: HHS, OIG.
233. FDA (Food and Drug Administration). 2000. FDA Guidance on Conflict of Interest for Advisory Committee Members, Consultants and Experts Table of Contents. [Online]. Available: http://www.fda.gov/oc/advisory/conflictofinterest/guidance.html [accessed July 13, 2006].
234. FDA. 2004. Innovation Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. [Online]. Available: http://www.fda.gov/oc/initiatives/criticalpath/ whitepaper.pdf [accessed October 10, 2005].
235. CBER (Center for Biologics Evaluation and Research), CDER (Center for Drug Evaluation and Research). 2006. Guidance Useful Written Consumer Medication Information (CMI). Rockville, MD: FDA.
236. CDER (Center for Drug Evaluation and Research). 2006. Medication Guides. [Online]. Available: http://www.fda.gov/cder/Offices/ODS/medication_guides.htm [accessed September 18, 2006].
237. DHHS, FDA, CDER. 2005a. FDA's Communication of Drug Safety Information: Transcript. [Online]. Available: http://www.fda.gov/cder/meeting/RiskComm2005/1207fda.pdf [accessed March, 2006].
238. DHHS, FDA, CDER. 2005b. FDA's Communication of Drug Safety Information: Transcript. [Online]. Available: http://www.fda.gov/cder/meeting/RiskComm2005/1208fda.pdf [accessed March, 2006].
239. Dupuits FMHM. 2002. The effects of the internet on pharmaceutical consumers and providers. Dis Manage Outcomes 10(11):679-691.
240. FDA (Food and Drug Administration). 2003. Advisory Committee Oversight and Management Staff. [Online]. Available: http://www.fda.gov/oc/advisory/missionandstaff.html [accessed April 18, 2006].
241. FDA. 2005. FDA's "Drug Watch" for Emerging Drug Safety Information Draft Guidance. Rockville, MD: FDA.
242. Galson S. 2005. Statement of Steven Galson, M.D., M.P.H, Acting Director Center for Drug Evaluation and Research, US Food and Drug Administration, Department of Health and Human Services, at the May 5, 2005, Committee on Government Reform, United States House of Representatives.
243. Greenberg MD. 2003. Information, paternalism, and rational decision-making: the balance of FDA new drug approval. Alb L J Sci & Tech Summer/Fall:1-16.
244. Henwood F, Wyatt S, Hart A, Smith J. 2003. "Ignorance is bliss sometimes": constraints on the emergence of the "informed patient" in the changing landscapes of health information. Sociol Health Illn 25(6):589-607.
245. IMS Health. 2006. IMS Health Reports Global Pharmaceutical Market Grew 7 Percent in 2005, to $ 602 Billion. [Online]. Available: http://www.imshealth.com/ims/portal/front/ articleC/0,2777,6599_3665_77491316,00.html [accessed August 28, 2006].
246. IOM (Institute of Medicine). 2005. Health Literacy: A Prescription to End Confusion. Washington, DC: The National Academies Press.
247. IOM. 2007. Preventing Medication Errors: Quality Chasm Series. Washington, DC: The National Academies Press.
248. Kaiser Family Foundation. 2004. Trends and Indicators in the Changing Health Care Marketplace. [Online]. Available: http://www.kff.org/insurance/7031/print-sec1.cfm [accessed October 10, 2005].
249. Meadows M. 2006. Keeping up with drug safety information. FDA Consumer Magazine May/June.
250. NCI (National Cancer Institute). 2006a. Director's Consumer Liaison Group: Charter Summary. [Online]. Available: http://deainfo.nci.nih.gov/advisory/dclg/dclgchr.htm [accessed April 20, 2006].
251. NCI. 2006b. Director's Consumer Liaison Group: Fact Sheet. [Online]. Available: http:// la.cancer.gov/DCLGFactSheet2006.pdf [accessed April 20, 2006].
252. NCI, Office of Liaison Activities. 2006c. Listening and Learning Together: Building a Bridge of Trust. [Online]. Available: http://www.palladianpartners.com/NCISummit2006/welcome. htm [accessed June 8, 2006].
253. NIH (National Institutes of Health). 2006. About COPR. [Online]. Available: http://copr.nih. gov/mission.asp [accessed July 13, 2006].
254. Pew Internet & American Life Project. 2003. Internet Health Resources: Health Searches and Email Have Become More Commonplace, but There Is Room for Improvement in Searches and Overall Internet Access. [Online]. Available: http://www.pewinternet.org/ pdfs/PIP_Health_Report_July_2003.pdf [accessed October 14, 2005].
255. Pew Internet & American Life Project. 2004. Prescription Drugs Online: One in Four Americans Have Looked Online for Drug Information, But Few Have Ventured into the Online Drug Marketplace. [Online]. Available: http://www.pewinternet.org/pdfs/PIP_Prescription_ Drugs_Online.pdf [accessed Octpber 17, 2005].
256. Pew Internet & American Life Project. 2005. Health Information Online: Eight in Ten Internet Users Have Looked for Health Information Online, With Increased Interest in Diet, Fitness, Drugs, Health Insurance, Experimental Treatments, and Particular Doctors and Hospitals. [Online]. Available: http://www.pewinternet.org/pdfs/PIP_Healthtopics_ May05.pdf [accessed October 17, 2005].
257. Smith C, Cowan C, Sensenig A, Catlin A, the Health Accounts Team. 2005. Health spending growth slows in 2003. Health Aff (Millwood) 24(1):185-194.
258. Steering Committee for the Collaborative Development of a Long-Range Action Plan for the Provision of Useful Prescription Medicine Information.1996. Action Plan for the Provision of Useful Prescription Medicine Information. [Online]. Available: http://www.fda. gov/cder/offices/ods/keystone.pdf [accessed July 18, 2006].
259. Throckmorton DC. 2006 (March 31). Drug Safety Oversight Board: Recent Activities. Power- Point presentation to the FDA Science Advisory Board. Bethesda, MD: FDA.
260. Woodcock J. 2002. Statement by Janet Woodcock, MD, Director, Center for Drug Administration Before the Subcommittee on Oversight and Investigations before the Committee on Energy and Commerce, US House of Representatives.NCI (National Cancer Institute). 2006a. Director's Consumer Liaison Group: Charter Summary. [Online]. Available: http://deainfo.nci.nih.gov/advisory/dclg/dclgchr.htm [accessed April 20, 2006].
261. NCI (National Cancer Institute). 2006a. Director's Consumer Liaison Group: Charter Summary. [Online]. Available: http://deainfo.nci.nih.gov/advisory/dclg/dclgchr.htm [accessed April 20, 2006].
262. NCI. 2006b. Director's Consumer Liaison Group: Fact Sheet. [Online]. Available: http:// la.cancer.gov/DCLGFactSheet2006.pdf [accessed April 20, 2006].
263. NCI, Office of Liaison Activities. 2006c. Listening and Learning Together: Building a Bridge of Trust. [Online]. Available: http://www.palladianpartners.com/NCISummit2006/welcome. htm [accessed June 8, 2006].
264. NIH (National Institutes of Health). 2006. About COPR. [Online]. Available: http://copr.nih. gov/mission.asp [accessed July 13, 2006].
265. Pew Internet & American Life Project. 2003. Internet Health Resources: Health Searches and Email Have Become More Commonplace, but There Is Room for Improvement in Searches and Overall Internet Access. [Online]. Available: http://www.pewinternet.org/ pdfs/PIP_Health_Report_July_2003.pdf [accessed October 14, 2005].
266. Pew Internet & American Life Project. 2004. Prescription Drugs Online: One in Four Americans Have Looked Online for Drug Information, But Few Have Ventured into the Online Drug Marketplace. [Online]. Available: http://www.pewinternet.org/pdfs/PIP_Prescription_ Drugs_Online.pdf [accessed Octpber 17, 2005].
267. Pew Internet & American Life Project. 2005. Health Information Online: Eight in Ten Internet Users Have Looked for Health Information Online, With Increased Interest in Diet, Fitness, Drugs, Health Insurance, Experimental Treatments, and Particular Doctors and Hospitals. [Online]. Available: http://www.pewinternet.org/pdfs/PIP_Healthtopics_ May05.pdf [accessed October 17, 2005].
268. Smith C, Cowan C, Sensenig A, Catlin A, the Health Accounts Team. 2005. Health spending growth slows in 2003. Health Aff (Millwood) 24(1):185-194.
269. Steering Committee for the Collaborative Development of a Long-Range Action Plan for the Provision of Useful Prescription Medicine Information.1996. Action Plan for the Provision of Useful Prescription Medicine Information. [Online]. Available: http://www.fda. gov/cder/offices/ods/keystone.pdf [accessed July 18, 2006].
270. Throckmorton DC. 2006 (March 31). Drug Safety Oversight Board: Recent Activities. Power- Point presentation to the FDA Science Advisory Board. Bethesda, MD: FDA.
271. Woodcock J. 2002. Statement by Janet Woodcock, MD, Director, Center for Drug Administration Before the Subcommittee on Oversight and Investigations before the Committee on Energy and Commerce, US House of Representatives.
272. Carpenter D, Ting MM. 2004. A Theory of Approval Regulation. [Online]. Available: http://people.hmdc.harvard.edu/~dcarpent/endosub-20040214.pdf [accessed October 10, 2005].
273. DHHS (Department of Health and Human Services), OIG (Office of Inspector General). 2003. FDA's Review Process for New Drug Applications: a Management Review. OEI-01-01- 00590. Washington, DC: OIG, FDA.
274. FDA (Food and Drug Administration). 2003. PDUFA III Five Year Plan. [Online]. Available: http://www.fda.gov/oc/pdufa3/2003plan/default.htm [accessed October 10, 2005].
275. FDA. 2005a. Center for Drug Evaluation and Research-Activities and Level of Effort Devoted to Drug Safety. Submitted to the Institute of Medicine Committee on the Assessment of the US Drug Safety System by FDA.
276. FDA. 2005b. White Paper, Prescription Drug User Fee Act (PDUFA): Adding Resources and Improving Performance in FDA Review of New Drug Applications. [Online]. Available: http://www.fda.gov/oc/pdufa/PDUFAWhitePaper.pdf [accessed December 5, 2005].
277. Federal News Service. 2000. Prepared Testimony of Richard Platt, MD, MSC, Professor of Ambulatory Care and Prevention Harvard Medical School Director of Research Harvard Pilgrim Health Care.
278. GAO. 2002. Food and Drug Administration: Effect of User Fees on Drug Approval Times, Withdrawals, and Other Agency Activities. GAO-02-958. Washington, DC: GAO.
279. GAO. 2006. Drug Safety: Improvement Needed in FDA's Postmarket Decision-Making and Oversight Process. GAO-06-402. Washington, DC: GAO.
280. Goldhammer A. 2005 (June 8). Statement of the Pharmaceutical Research and Manufacturers of America to Institute of Medicine. Presentation to the Institute of Medicine Committee on the Assessment of the US Drug Safety System. Washington, DC: IOM.
281. Laffont J, Tirole J. 1991. The politics of government decision-making: a theory of regulatory capture. Quart J Econ 106(4):1089-1127.
282. Stigler G. 1971. The theory of economic regulation. Bell J Econ Manage Sci 2:2-21.
283. Thompson L. 2000. User fees for faster drug reviews. Are they helping or hurting the public health? FDA Consum 34(5):25-29.
284. Union of Concerned Scientists (UCS). 2006. FDA Scientists Pressured to Exclude, Alter Findings; Scientists Fear Retaliation for Voicing Safety Concerns. [Online]. Available: http://www.ucsusa.org/news/press_release/fda-scientists-pressured.html [accessed July 24, 2006].
285. Wolfe S. 2006. Public Citizen: The 100th Anniversary of the FDA: The Sleeping Watchdog Whose Master Is Increasingly the Regulated Industries. [Online]. Available: http://www. pharmalive.com/News/index.cfm?articleid=353196&categoryid=54 [accessed July 11, 2006].
286. Zelenay JL. 2005. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration? Food Drug Law J 60(2):261-338.